AstraZeneca plc’s (AZN) “Hold” Rating Reiterated at Shore Capital
Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. restated a neutral rating and set a GBX 4,800 ($59.46) price objective on shares of AstraZeneca plc in a research report on Thursday, July 21st. Jefferies Group boosted their price objective on shares of AstraZeneca plc from GBX 4,600 ($56.98) to GBX 4,800 ($59.46) and gave the company a hold rating in a research note on Thursday, July 14th. HSBC set a GBX 4,815 ($59.64) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Tuesday, August 2nd. Beaufort Securities reissued a hold rating on shares of AstraZeneca plc in a research note on Wednesday, August 10th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($49.55) price target on shares of AstraZeneca plc and gave the stock a sell rating in a research note on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. AstraZeneca plc presently has an average rating of Hold and a consensus price target of GBX 4,947.72 ($61.29).
AstraZeneca plc (LON:AZN) opened at 4356.50 on Wednesday. The firm’s market cap is GBX 55.11 billion. The firm’s 50-day moving average is GBX 4,837.61 and its 200-day moving average is GBX 4,555.57. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.